To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Summary

This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation used the eczema area and severity score and the overall investigator score to confirm the efficacy.

Timeline

Start

2024-10-08

Primary completion

2025-09-11

Completion

2026-06

Outcome

Met primary endpoint

release “TQH2722-Ⅲ-01是一项TQH2722治疗中重度特应性皮炎的多中心、随机、双盲、安慰剂对照Ⅲ期临床试验研究，共入组500例患者。此次上市申请获受理基于该研究取得的积极临床结果，共同主要终点第16周EASI-75应答率和IGA 0/1应答率均已达到” cttq.com ↗

Drugs

Indications